All In Biotech

Drug Trial Radar · NCT07082764

Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

A Phase 2a Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Sep 30, 2026

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Tarian PharmaIndustry
Sponsor type
Industry
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Taxane -induced peripheral neuropthy (TIPN) and nail toxicites are frequent side effects of taxane therapy in breast cancer patients.. TIPN involves the hands and the feet ,its symptoms comprise numbness,tingling,altered touch sensation, impaired vibration, parasthesia and dysesthesias induced by touch, warm or cool temperatures. This study investigate the preventive effect of TAR-0520 gel on TIPN and on nail toxicity. Breast cancer patients under taxanes therapy will apply TAR-0520 Gel to one hand and the homolateral foot including fingers and toes. Other hand and foot will be untreated and will serve as control. Patients will be followed during the 12 cycles of taxane therapy. Evaluations of TIPN will include clinical assessments by the oncologist, examination by a neurologist, patient questionnaires administered by a nurse and objective neurophysiological measures conducted by trained personnel. Evaluation of taxane nail toxicity will include a clinical grading by a nurse and a patient questionnaire.

Conditions

  • Chemotherapy Induced Peripheral Neuropathy

Interventions

  • Brimonidine gelDrug

    TAR-0520 gel

  • No intervantionOther

    No treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment related local adverse eventsTime frame: From Baseline up to the end of 12 taxane perfusions

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut Paoli-Calmettes

    Marseille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.